Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Oral iron supplementation: new formulations, old questions

Pantopoulos, Kostas·2024·Haematologica
DOI 10.3324/haematol.2024.284967
Open this paper in CoChat — free account

Abstract

Iron-deficiency anemia and pre-anemic iron deficiency are the most frequent pathologies. The first line of treatment involves oral iron supplementation. The simplest, least expensive, and most commonly prescribed drug is ferrous sulfate, while other ferrous salts and ferric complexes with polysaccharides or succinylated milk proteins are also widely used. In recent years, novel iron formulations have been developed, such as the lipophilic iron donor ferric maltol, or nanoparticle encapsulated sucrosomial® iron. Oral iron supplementation is usually efficacious in correcting iron-deficiency anemia and replenishing iron stores but causes gastrointestinal side effects that reduce compliance. When oral iron supplementation is contraindicated, intravenous iron therapy can rapidly achieve therapeutic targets without gastrointestinal complications. Herein, we critically review literature on relative efficacy and tolerability of currently available oral iron supplements, and summarize recent data on optimal dosage and frequency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2024.284967

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 87

  1. Katsarou A, Pantopoulos K. Basics and principles of cellular and systemic iron homeostasis. Mol Aspects Med. 2020; 75:100866. · DOI
  2. Charlebois E, Pantopoulos K. Nutritional aspects of iron in health and disease. Nutrients. 2023; 15(11):2441. · DOI
  3. Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2014; 307(4):G397-G409. · DOI · Paper page
  4. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron absorption: factors, limitations, and improvement methods. ACS Omega. 2022; 7(24):20441-20456. · DOI · Paper page
  5. Hooda J, Shah A, Zhang L. Heme, an essential nutrient from dietary proteins, critically impacts diverse physiological and pathological processes. Nutrients. 2014; 6(3):1080-1102. · DOI
  6. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023; 74:261-277. · DOI · Paper page
  7. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021; 397(10270):233-248. · DOI · Paper page
  8. Drakesmith H, Pasricha SR, Cabantchik I. Vaccine efficacy and iron deficiency: an intertwined pair?. Lancet Haematol. 2021; 8(9):e666-e669. · DOI
  9. GBD. Anemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2021; 10(9):e713-e734.
  10. da Silva Lopes K, Yamaji N, Rahman MO. Nutrition-specific interventions for preventing and controlling anaemia throughout the life cycle: an overview of systematic reviews. Cochrane Database Syst Rev. 2021; 9(9):CD013092. · DOI
  11. Nielsen OH, Soendergaard C, Vikner ME, Weiss G. Rational management of iron-deficiency anaemia in inflammatory bowel disease. Nutrients. 2018; 10(1):82. · DOI
  12. Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis. 2019; 26(4):272-291. · DOI
  13. Gowanlock Z, Lezhanska A, Conroy M. Iron deficiency following bariatric surgery: a retrospective cohort study. Blood Adv. 2020; 4(15):3639-3647. · DOI
  14. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019; 133(1):40-50. · DOI · Paper page
  15. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018; 107(1):16-30. · DOI
  16. Lo JO, Benson AE, Martens KL. The role of oral iron in the treatment of adults with iron deficiency. Eur J Haematol. 2023; 110(2):123-130. · DOI
  17. Celis AI, Relman DA, Huang KC. The impact of iron and heme availability on the healthy human gut microbiome in vivo and in vitro. Cell Chem Biol. 2023; 30(1):110-126. · DOI
  18. Jaeggi T, Kortman GA, Moretti D. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015; 64(5):731-742. · DOI · Paper page
  19. Mayneris-Perxachs J, Cardellini M, Hoyles L. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome. 2021; 9(1):104. · DOI
  20. Shah AA, Donovan K, Seeley C. Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. JAMA Netw Open. 2021; 4(11):e2133935. · DOI
  21. Schaefer B, Tobiasch M, Wagner S. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022; 154:116202. · DOI
  22. Rampton D, Folkersen J, Fishbane S. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014; 99(11):1671-1676. · DOI · Paper page
  23. Feng Y, Wassie T, Wu Y, Wu X. Advances on novel iron saccharide-iron (III) complexes as nutritional supplements. Crit Rev Food Sci Nutr. 2023. · DOI
  24. Kontoghiorghes GJ, Kolnagou A, Demetriou T, Neocleous M, Kontoghiorghe CN. New era in the treatment of iron deficiency anaemia using trimaltol iron and other lipophilic iron chelator complexes: historical perspectives of discovery and future applications. Int J Mol Sci. 2021; 22(11):5546. · DOI
  25. Gomez-Ramirez S, Brilli E, Tarantino G, Munoz M. Sucrosomial® iron: a new generation iron for improving oral supplementation. Pharmaceuticals (Basel). 2018; 11(4):97. · DOI · Paper page
  26. Pisani A, Riccio E, Sabbatini M. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015; 30(4):645-652. · DOI
  27. Singh K, Sethi Chopra D, Singh D, Singh N. Nano-formulations in treatment of iron deficiency anaemia: an overview. Clin Nutr ESPEN. 2022; 52:12-19. · DOI
  28. Cupone IE, Roselli G, Marra F. Orodispersible film based on maltodextrin: a convenient and suitable method for iron supplementation. Pharmaceutics. 2023; 15(6):1575. · DOI
  29. Huebers HA, Brittenham GM, Csiba E, Finch CA. Absorption of carbonyl iron. J Lab Clin Med. 1986; 108(5):473-478.
  30. Seligman PA, Moore GM, Schleicher RB. Clinical studies of hip: an oral heme-iron product. Nutr Res. 2000; 20(9):1279-1286. · DOI
  31. Conway RE, Geissler CA, Hider RC, Thompson RP, Powell JJ. Serum iron curves can be used to estimate dietary iron bioavailability in humans. J Nutr. 2006; 136(7):1910-1914. · DOI
  32. Hoppe M, Hulthen L, Hallberg L. The validation of using serum iron increase to measure iron absorption in human subjects. Br J Nutr. 2004; 92(3):485-488. · DOI
  33. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011; 3(1):12-33. · DOI
  34. Wienk KJ, Marx JJ, Beynen AC. The concept of iron bioavailability and its assessment. Eur J Nutr. 1999; 38(2):51-75. · DOI
  35. Dignass AU, Gasche C, Bettenworth D. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015; 9(3):211-222. · DOI · Paper page
  36. Ning S, Zeller MP. Management of iron deficiency. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):315-322. · DOI
  37. Snook J, Bhala N, Beales ILP. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021; 70(11):2030-2051. · DOI · Paper page
  38. Rudinskas L, Paton TW, Walker SE, Dotten DA, Cowan DH. Poor clinical response to enteric-coated iron preparations. CMAJ. 1989; 141(6):565-566.
  39. Thankachan P, Bose B, Subramanian R, Koneri R, Kurpad AV. Fractional iron absorption from enteric-coated ferrous sulphate tablet. Indian J Med Res. 2020; 151(4):371-374. · DOI
  40. Delorme MA, Inwood MJ, Gwadry-Sridhar F. Enteric-coated iron tablets. CMAJ. 1990; 142(1):12-13.
  41. Powers JM, Buchanan GR, Adix L. Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia: a randomized clinical trial. JAMA. 2017; 317(22):2297-2304. · DOI
  42. Berber I, Diri H, Erkurt MA. Evaluation of ferric and ferrous iron therapies in women with iron deficiency anaemia. Adv Hematol. 2014; 2014:297057. · DOI
  43. Martinez Frances A, Leal Martinez-Bujanda J. Efficacy and tolerability of oral iron protein succinylate: a systematic review of three decades of research. Curr Med Res Opin. 2020; 36(4):613-623. · DOI
  44. Urso K, Leal Martinez-Bujanda J, Del Prado JM. Iron protein succinylate in the management of iron deficiency anemia: a comparative study with ferrous sulphate at low and high therapeutic doses. Nutrients. 2021; 13(3):968. · DOI
  45. Fishbane S, Block GA, Loram L. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 2017; 28(6):1851-1858. · DOI
  46. Womack R, Berru F, Panwar B, Gutierrez OM. Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial. Clin J Am Soc Nephrol. 2020; 15(9):1251-1258. · DOI
  47. Schmidt C, Allen S, Kopyt N, Pergola P. Iron replacement therapy with oral ferric maltol: review of the evidence and expert opinion. J Clin Med. 2021; 10(19):4448. · DOI
  48. Howaldt S, Domenech E, Martinez N, Schmidt C, Bokemeyer B. Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial. Inflamm Bowel Dis. 2022; 28(3):373-384. · DOI
  49. Gomez-Ramirez S, Brilli E, Tarantino G, Girelli D, Munoz M. Sucrosomial® iron: an updated review of its clinical efficacy for the treatment of iron deficiency. Pharmaceuticals (Basel). 2023; 16(6):847. · DOI
  50. Abbati G, Incerti F, Boarini C. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med. 2019; 14(3):423-431. · DOI
  51. de Alvarenga Antunes CV, de Alvarenga Nascimento CR, Campanha da Rocha Ribeiro T. Treatment of iron deficiency anemia with liposomal iron in inflammatory bowel disease: efficacy and impact on quality of life. Int J Clin Pharm. 2020; 42(3):895-902. · DOI
  52. Hussain U, Zia K, Iqbal R, Saeed M, Ashraf N. Efficacy of a novel food supplement (Ferfer®) containing microencapsulated iron in liposomal form in female iron deficiency anemia. Cureus. 2019; 11(5):e4603. · DOI
  53. Gordeuk VR, Brittenham GM, McLaren CE, Hughes MA, Keating LJ. Carbonyl iron therapy for iron deficiency anemia. Blood. 1986; 67(3):745-752. · DOI
  54. Gordeuk VR, Brittenham GM, Bravo J, Hughes MA, Keating LJ. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion. 1990; 30(3):239-245. · DOI
  55. Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr. 1987; 46(6):1029-1034. · DOI
  56. Barraclough KA, Brown F, Hawley CM. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant. 2012; 27(11):4146-4153. · DOI
  57. Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol. 2013; 14:64. · DOI
  58. Friling M, Garcia-Munoz AM, Perrinjaquet-Moccetti T. Tolerability of oral supplementation with microencapsulated ferric saccharate compared to ferrous sulphate in healthy premenopausal woman: a crossover, randomized, double-blind clinical trial. Int J Mol Sci. 2022; 23(20):12282. · DOI
  59. Chertow GM, Block GA, Neylan JF. Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One. 2017; 12(11):e0188712. · DOI
  60. Gasche C, Ahmad T, Tulassay Z. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015; 21(3):579-588. · DOI
  61. Schmidt C, Ahmad T, Tulassay Z. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016; 44(3):259-270. · DOI
  62. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021; 78(6):846-856.e1. · DOI
  63. Giordano G, Napolitano M, Di Battista V, Lucchesi A. Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study. Ann Hematol. 2021; 100(9):2173-2179. · DOI
  64. Antoine E, Mehedintu C, Mitran M, Diculescu D. Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period. BMC Pregnancy Childbirth. 2023; 23(1):360. · DOI
  65. Mwangi MN, Mzembe G, Moya E, Verhoef H. Iron deficiency anaemia in sub-Saharan Africa: a review of current evidence and primary care recommendations for high-risk groups. Lancet Haematol. 2021; 8(10):e732-e743. · DOI
  66. Hutchinson C, Al-Ashgar W, Liu DY. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest. 2004; 34(11):782-784. · DOI
  67. Dresow B, Petersen D, Fischer R, Nielsen P. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals. 2008; 21(3):273-276. · DOI
  68. Schumann K, Solomons NW, Romero-Abal ME. Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men. Food Nutr Bull. 2012; 33(2):128-136. · DOI
  69. Tuomainen TP, Nyyssönen K, Porkkala-Sarataho E. Oral supplementation with ferrous sulfate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutr Res. 1999; 19(8):1121-1132. · DOI
  70. Toblli JE, Cao G, Angerosa M. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats. Drug Des Devel Ther. 2015; 9:2585-2597. · DOI
  71. Asperti M, Gryzik M, Brilli E. Sucrosomial® iron supplementation in mice: effects on blood parameters, hepcidin, and inflammation. Nutrients. 2018; 10(10):1349. · DOI
  72. Kavakli K, Yilmaz D, Cetinkaya B. Safety profiles of Fe2+ and Fe3+ oral preparations in the treatment of iron deficiency anemia in children. Pediatr Hematol Oncol. 2004; 21(5):403-410. · DOI
  73. Lee T, Clavel T, Smirnov K. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017; 66(5):863-871. · DOI · Paper page
  74. Constante M, Fragoso G, Lupien-Meilleur J, Calve A, Santos MM. Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2017; 23(5):753-766. · DOI
  75. Mahalhal A, Frau A, Burkitt MD. Oral ferric maltol does not adversely affect the intestinal microbiome of patients or mice, but ferrous sulphate does. Nutrients. 2021; 13(7):2269. · DOI
  76. Zakrzewski M, Wilkins SJ, Helman SL. Supplementation with sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice. Biometals. 2022; 35(1):27-38. · DOI
  77. Raza GS, Putaala H, Hibberd AA. Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice. Sci Rep. 2017; 7(1):5294. · DOI
  78. Moretti D, Goede JS, Zeder C. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015; 126(17):1981-1989. · DOI · Paper page
  79. Kaundal R, Bhatia P, Jain A. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol. 2020; 99(1):57-63. · DOI
  80. Duzen Oflas N, Demircioglu S, Yildirim Dogan N. Comparison of the effects of oral iron treatment every day and every other day in female patients with iron deficiency anaemia. Intern Med J. 2020; 50(7):854-858. · DOI
  81. Kaynar LA, Gokcen S, Can F. Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia. Ann Hematol. 2022; 101(7):1459-1464. · DOI
  82. Pasupathy E, Kandasamy R, Thomas K, Basheer A. Alternate day versus daily oral iron for treatment of iron deficiency anemia: a randomized controlled trial. Sci Rep. 2023; 13(1):1818. · DOI
  83. Fernandez-Gaxiola AC, De-Regil LM. Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women. Cochrane Database Syst Rev. 2019; 1(1):CD009218. · DOI
  84. Wittker MC, Farrag K, Schröder O, Aksan A, Stein J. Iron maltol versus ferrous sulphate in IBD-related anemia: does choice of iron compound make a difference to serum hepcidin levels?. Am J Gastroenterology. 2022; 117:S16-17. · DOI
  85. Hanudel MR, Czaya B, Wong S. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. Kidney Int. 2022; 101(4):711-719. · DOI
  86. Asperti M, Brilli E, Denardo A. Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments. Am J Hematol. 2021; 96(10):1253-1263. · DOI
  87. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014; 28(4):637-652. · DOI

Cited by

See all 78

Metadata

Authors
Pantopoulos, K.
Venue
Haematologica
Publisher
Ferrata Storti Foundation (Haematologica)
Published
2024-04-11
Volume
109
Issue
9
Pages
2790-2801
ISSN
  • 1592-8721
  • 0390-6078
DOI
10.3324/haematol.2024.284967
Cited by
78
References
12
Licence
creativecommons.org/licenses/by-nc/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.